Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of recombinant human albumin injection (rice-derived) in emergency treatment of hypoalbuminemia and/or hypovolemia
CTR20260659Phase 4Active
- Sponsor
- Wuhan Healthgen Biotechnology Corp.
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of albumin (human) in hypoalbuminemia, Cirrhosis, hypovolemia, sponsored by Wuhan Healthgen Biotechnology Corp.. Started Mar 2026; status: active.
02
Drugs
albumin (human)
03
Conditions
hypoalbuminemiaCirrhosishypovolemia
Beyond the preview
Go deeper on CTR20260659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260659.